Syngene

About Syngene

Syngene International Ltd. operates as a contract research, development, and manufacturing organization (CRDMO), providing integrated scientific services from early-stage discovery to commercial supply. The company was established on November 18, 1993, in Bengaluru, India, by Kiran Mazumdar-Shaw as a subsidiary of Biocon, her pioneering biotechnology enterprise. Mazumdar-Shaw, a first-generation entrepreneur with over four decades of experience in biotechnology, started Biocon in 1978 and has been instrumental in shaping India's biotech landscape. Her vision for Syngene was to create India's first contract research organization (CRO) to support the R&D programs of global innovative companies.

Syngene's business model is structured to serve as a comprehensive partner for a diverse clientele that includes companies in the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Its revenue is generated through a flexible fee-for-service model, long-term contracts, and the establishment of dedicated R&D centers for key clients, which ensures a steady stream of income. The company serves over 400 active clients, including 13 of the top 15 global pharmaceutical companies, ranging from large multinationals to startups and academic institutions. Syngene acts as an extension of its clients' internal scientific teams, offering end-to-end services across the entire drug discovery and development value chain.

Key services are categorized into Discovery, Development, and Manufacturing. Discovery services cover the early stages of research, from target identification to delivering drug candidates. Development services encompass preclinical to clinical trial activities, including drug substance and product development for both small and large molecules. The company's manufacturing arm provides cGMP-compliant production from small volumes for clinical supplies to commercial scale. A notable offering is SynVent, a proprietary platform for fully integrated therapeutic discovery and development. This integrated approach allows for a more efficient and seamless R&D process, reducing time-to-market for new products. The company's infrastructure includes over 2.5 million square feet of specialized facilities across Bangalore, Hyderabad, and Mangalore, operated by a team of over 5,600 scientists.